News

Spur Therapeutics to Unveil Promising Gene Therapy Data

Spur Therapeutics to Unveil Promising Gene Therapy Data

Spur Therapeutics Prepares for ESGCT Annual Congress Presentation

Recently, Spur Therapeutics announced plans to present groundbreaking clinical data regarding its gene therapy candidate, avigbagene parvec (FLT201), targeting Gaucher disease. This significant presentation is scheduled to occur during the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress, which will be held from October 7-10.

Essential Details of the Presentation

The presentation titled, "Long-term durability of FLT201: an investigational gene therapy for Gaucher disease Type 1 encoding an engineered variant of the GCase enzyme," will be pivotal in showcasing the advancements of this innovative therapy. Scheduled for October 8, 2025, from 14:00 to 15:30 CEST (8:00 to 9:30 a.m. EST), the session will be presided over by Dr. Pilar Giraldo from Hospital Universitario Quironsalud.

Link to Abstracts

Abstracts related to this presentation are now accessible on the official ESGCT website, making essential insights available to the public and industry stakeholders alike.

About Spur Therapeutics

As a clinical-stage biotechnology company, Spur Therapeutics is dedicated to the development of pioneering gene therapies aimed at alleviating chronic debilitating conditions. The company believes in optimizing every component of its product candidates to unleash the full potential of gene therapy, thereby achieving remarkable clinical outcomes.

Clinical Impacts and Aspirations

Notably, Spur is in the process of advancing not only its lead candidate for Gaucher disease but also a preclinical gene therapy targeting Parkinson's disease. This dual focus illustrates Spur's commitment to expanding its impact in the realm of genetic medicine and pursuing life-changing therapies that lead to brighter futures for patients.

Connecting with Spur Therapeutics

For further inquiries or information, individuals can reach out to Naomi Aoki via email at naomi.aoki@spurtherapeutics.com or call +1 617 283 4298. Spur also maintains an engaging online presence; interested parties are invited to visit their website at www.spurtherapeutics.com or connect via LinkedIn.

Frequently Asked Questions

What is the primary focus of Spur Therapeutics?

Spur Therapeutics primarily focuses on developing gene therapies for chronic conditions, notably Gaucher disease and Parkinson's disease.

When will Spur present at the ESGCT Congress?

Spur Therapeutics is set to present on October 8, 2025, at the ESGCT Annual Congress.

Who is presenting the data on FLT201?

The presentation will be delivered by Dr. Pilar Giraldo from Hospital Universitario Quironsalud.

How can I access the abstracts from the presentation?

The abstracts are available on the ESGCT website for public access.

Where can I find more information about Spur Therapeutics?

More information can be found on their official website at www.spurtherapeutics.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Jon Hamm & BetMGM: A New Play Unveiled for Fans

Updated Category News Views 7

Setting the Stage: BetMGM's Latest Move BetMGM is shaking things up as the head honcho in the sports betting realm by letting Jon Hamm lead the charge with their new campaign, "It Happens Here." Now, what does this spell for the hardcore fans and bettors? A fresh stadium to play in. Not just any arena, mind you, but a blend of sportsbook excitement, gaming, entertainment,...

Continue Reading
Sublime Integrates Email Security with Falcon SIEM

Updated Category News Views 8

Cybersecurity Taking a Leap Forward Seems like everyone and their grandmother knows that email's a battleground these days. Well, here's a twist: Sublime Security's joining hands with CrowdStrike's Falcon Next-Gen SIEM to give security pros a little extra edge in the fight. They've announced this integration at FAL.CON 2026, and they're betting it's gonna speed up...

Continue Reading
Aon's Bold $17B Move to Transform US Mid-Market

Updated Category News Views 3

Aon and USI: The $17B Gamble In a market that's tougher than a $2 steak, Aon's stepping up with a $17 billion bid to nab USI. This isn't just another paint-by-numbers acquisition; it's a high-stakes move to become the heavyweight champ of the U.S. middle-market insurance sector. Aon's looking to outgrow the competition by boosting its niche in the Excess & Surplus (E&S)...

Continue Reading
Latham & Watkins' Strategic Moves Spark Asian Market

Updated Category News Views 2

Setting the Stage for Expansion When you hear that Grace Huang and Edward Freeman are hopping onto Latham & Watkins' Hong Kong ship, it's a bit like watching heavyweights enter the ring. Both these pros are bringing a truckload of experience into one of Asia's most competitive markets. This isn't just a small change; it’s a pretty big deal for the firm's capital markets...

Continue Reading
PrimeBOT Unveils Game-Changing Robots at IFA 2026

Updated Category News Views 6

PrimeBOT Ushers in a New Era of Personal Robotics Bodies and brains made of metal marching into the future—no, it's not science fiction, it's PrimeBOT at IFA 2026. PrimeBOT is rolling out two head-turning robots, the PrimeBOT T1 and PrimeBOT Q1, with ambitions to infiltrate our daily lives. The company's vision for 'Creating a Better Life through Embodied Intelligence'...

Continue Reading
BGM Makes Strategic Northeast Acquisition with JTC

Updated Category News Views 8

Why BGM's Expansion Matters No fireworks or confetti cannons here, just old-fashioned strategic growth. BGM, perched comfortably in the Top 200 echelon, has made a shrewd move by merging with John T. Chipman & Company, LLP (JTC). This isn't just any merger—it's about broadening horizons, planting roots, and cementing relationships in the Northeast, specifically in the...

Continue Reading
US and NABEP Strike $100B Venezuela Oil Deal

Updated Category News Views 5

Historic Pact to Transform the Venezuelan Oil Scene Sit tight, because the United States and North American Blue Energy Partners (NABEP) are rocking the oil world with a contract that's hotter than a summer heatwave. We're talking about close to $100 billion thrown into commercializing over 65 billion barrels of P1 reserves in Venezuela. Yeah, you read that right. A $100...

Continue Reading
Celebrities Unite for Iconic Dance Party to End ALZ

Updated Category News Views 1

An Event Rooted in Community and Cause Movies and glitter aren't the only things coming out of Hollywood. On September 13, the glamorous AVALON Hollywood will transform into a beacon of hope for Alzheimer's research. Hosting the iconic event, Hallmark luminaries Ashley Williams and Nikki DeLoach—and teamed up with emcees Jonathan Bennett and Melissa Peterman—are ready...

Continue Reading
Three Lions Acquisition Corp. IPO: Key Insights

Updated Category News Views 6

IPO Pricing: Dive into the Numbers Three Lions Acquisition Corp. has thrown its hat in the ring with a $100 million initial public offering. They're pushing 10 million units at $10 a pop, and let's face it, in this day and age, raising a cool $100 million is no small feat. Especially when you're talking about a special purpose acquisition company, or SPAC. The SPAC Angle:...

Continue Reading
Dengue Fever Strikes Florida: Mosquito Measures Intensified

Updated Category News Views 10

Dengue Cases Surge: A Community Alert Florida's dance with dengue fever isn't new, but this year's count is gnawing at the sunshine state's comfort zone. With over 40 locally-acquired cases spreading their unwelcome presence, the Florida Mosquito Control Association (FMCA) is buzzing about prevention. I mean, nobody wants to host the mosquito cocktail party, right? Well,...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackRock MuniYield Quality Fund Reaches New Performance Heights

Updated Category News Views 63

BlackRock MuniYield Quality Fund III (MYI) hit a remarkable 52-week high back in 2024, trading at $12.02. This milestone wasn’t just another number on the board; it marked an impressive recovery for the fund in a shaky investment landscape. The share price increase of 25.76% over that year drew attention from traders looking for stability among municipal bonds. Market...

Continue Reading
Ninja Partners with La Roche-Posay for Skin Health Awareness

Updated Category News Views 353

Ninja Partners with La Roche-Posay for Skin Health Awareness In an exceptional alliance aimed at raising awareness about skin cancer detection and prevention, Ninja has officially partnered with La Roche-Posay. This strategic collaboration sets out to combine Ninja’s widespread influence with La Roche-Posay's commitment to skincare education and health initiatives....

Continue Reading
Chorus Aviation's Latest Financial Report Shows Promising Trends

Updated Category News Views 354

Chorus Aviation Inc. Delivers Fourth Quarter Financial Overview Chorus Aviation Inc. has recently unveiled its financial results for the fourth quarter and year-end of 2024, showcasing a significant transformation in their financial landscape. This announcement comes on the heels of strategic actions aimed at enhancing the company's market position and efficiency. Key...

Continue Reading
ICON plc's Resilience Amid Market Challenges and Analyst Opinions

Updated Category News Views 110

ICON plc Maintains Its Analyst Rating in Tough Market Conditions Recently, ICON plc (NASDAQ: ICLR) has managed to retain its Outperform rating as evaluated by Leerink Partners, despite the visible market pressures impacting its performance in the last quarter. The firm has reaffirmed a price target of $376.00 for the shares of ICON, reflecting a positive outlook amidst...

Continue Reading
Gabriele Cerrone Increases Stake in OKYO Pharma Limited

Updated Category News Views 136

Significant Share Acquisition by OKYO Pharma Chairman In a notable development in the biopharmaceutical world, OKYO Pharma Limited (NASDAQ: OKYO), known for its focus on ophthalmology, has revealed that Gabriele Cerrone, the Executive Chairman of the company, has increased his shareholding. He has acquired 82,018 ordinary shares in the company through Panetta Partners...

Continue Reading